DAVIS JAMES H 4
4 · HUMAN GENOME SCIENCES INC · Filed Aug 1, 2012
Insider Transaction Report
Form 4
DAVIS JAMES H
Exec. VP, Gen Counsel & Sec.
Transactions
- Disposition from Tender
Common Stock
2012-07-30$14.25/sh−165,032$2,351,706→ 0 total - Disposition to Issuer
Employee Stock Option - Right to Buy
2012-07-30$14.25/sh−118,827$1,693,285→ 0 totalExercise: $10.62Exp: 2017-03-10→ Common Stock (118,827 underlying) - Disposition to Issuer
Employee Stock Option - Right to Buy
2012-07-30$14.25/sh−119,473$1,702,490→ 0 totalExercise: $0.52Exp: 2019-03-10→ Common Stock (119,473 underlying) - Disposition to Issuer
Employee Stock Option - Right to Buy
2012-07-30$14.25/sh−89,828$1,280,049→ 0 totalExercise: $12.56Exp: 2015-01-17→ Common Stock (89,828 underlying) - Disposition to Issuer
Employee Stock Option - Right to Buy
2012-07-30$14.25/sh−87,002$1,239,779→ 0 totalExercise: $10.89Exp: 2016-03-14→ Common Stock (87,002 underlying) - Disposition to Issuer
Employee Stock Option - Right to Buy
2012-07-30$14.25/sh−138,031$1,966,942→ 0 totalExercise: $4.92Exp: 2018-03-10→ Common Stock (138,031 underlying) - Disposition to Issuer
Employee Stock Option - Right to Buy
2012-07-30$14.25/sh−108,000$1,539,000→ 0 totalExercise: $8.23Exp: 2022-03-10→ Common Stock (108,000 underlying) - Disposition to Issuer
Employee Stock Option - Right to Buy
2012-07-30$14.25/sh−91,923$1,309,903→ 0 totalExercise: $12.38Exp: 2013-12-10→ Common Stock (91,923 underlying)
Footnotes (7)
- [F1]This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $151,809.32, representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc.These options vested automatically upon consummation of the tender offer on July 30, 2012.
- [F2]This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $431,342.01, representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc.These options vested automatically upon consummation of the tender offer on July 30, 2012.
- [F3]This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $1,287,829.23, representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc.These options vested automatically upon consummation of the tender offer on July 30, 2012.
- [F4]This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $1,640,364.29, representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc.These options vested automatically upon consummation of the tender offer on July 30, 2012.
- [F5]This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $650,160.00, representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc.These options vested automatically upon consummation of the tender offer on July 30, 2012.
- [F6]This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $292,326.72, representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc.These options vested automatically upon consummation of the tender offer on July 30, 2012.
- [F7]This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $171,896.01, representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc.These options vested automatically upon consummation of the tender offer on July 30, 2012.